A Double-Blind, Randomized, Placebo-Controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs Dexmecamylamine (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 08 Aug 2009 Actual number of patients (1) added as reported by ClinicalTrials.gov.
    • 08 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Jul 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top